Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.72 Billion CNY | -41.2% |
| 2022 | 2.94 Billion CNY | 49.82% |
| 2021 | 1.96 Billion CNY | 1.28% |
| 2020 | 1.94 Billion CNY | 43.57% |
| 2019 | 1.35 Billion CNY | 34.29% |
| 2018 | 1 Billion CNY | 43.54% |
| 2017 | 701.04 Million CNY | 87.0% |
| 2016 | 374.89 Million CNY | 30.95% |
| 2015 | 286.3 Million CNY | 20.78% |
| 2014 | 237.04 Million CNY | 65.61% |
| 2013 | 143.13 Million CNY | 23.88% |
| 2012 | 115.54 Million CNY | 27.24% |
| 2011 | 90.8 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 370.13 Million CNY | -5.15% |
| 2024 Q2 | 390.22 Million CNY | -31.29% |
| 2024 Q1 | 567.9 Million CNY | 20.42% |
| 2023 FY | 1.73 Billion CNY | -41.2% |
| 2023 Q1 | 543.04 Million CNY | 31.9% |
| 2023 Q4 | 471.61 Million CNY | 50.47% |
| 2023 Q2 | 403.04 Million CNY | -25.78% |
| 2023 Q3 | 313.43 Million CNY | -22.23% |
| 2022 Q2 | 603.71 Million CNY | -64.02% |
| 2022 Q1 | 1.67 Billion CNY | 426.71% |
| 2022 Q4 | 411.69 Million CNY | 64.18% |
| 2022 Q3 | 250.75 Million CNY | -58.46% |
| 2022 FY | 2.94 Billion CNY | 49.82% |
| 2021 Q4 | 318.52 Million CNY | -13.92% |
| 2021 Q1 | 491.1 Million CNY | 27.42% |
| 2021 Q2 | 785.3 Million CNY | 59.9% |
| 2021 FY | 1.96 Billion CNY | 1.28% |
| 2021 Q3 | 370.02 Million CNY | -52.88% |
| 2020 Q3 | 421.84 Million CNY | -44.57% |
| 2020 Q2 | 761.02 Million CNY | 104.69% |
| 2020 Q1 | 371.79 Million CNY | -12.02% |
| 2020 FY | 1.94 Billion CNY | 43.57% |
| 2020 Q4 | 385.41 Million CNY | -8.64% |
| 2019 Q3 | 297.89 Million CNY | -15.45% |
| 2019 Q2 | 352.32 Million CNY | 26.51% |
| 2019 FY | 1.35 Billion CNY | 34.29% |
| 2019 Q4 | 422.59 Million CNY | 41.86% |
| 2019 Q1 | 278.49 Million CNY | -9.31% |
| 2018 Q3 | 213.35 Million CNY | -20.76% |
| 2018 Q2 | 269.24 Million CNY | 24.31% |
| 2018 Q1 | 216.6 Million CNY | -4.41% |
| 2018 FY | 1 Billion CNY | 43.54% |
| 2018 Q4 | 307.08 Million CNY | 43.93% |
| 2017 Q4 | 226.58 Million CNY | 22.44% |
| 2017 Q1 | 115.16 Million CNY | 5.91% |
| 2017 Q2 | 174.22 Million CNY | 51.28% |
| 2017 FY | 701.04 Million CNY | 87.0% |
| 2017 Q3 | 185.06 Million CNY | 6.22% |
| 2016 FY | 374.89 Million CNY | 30.95% |
| 2016 Q4 | 108.73 Million CNY | 17.7% |
| 2016 Q3 | 92.38 Million CNY | -10.94% |
| 2016 Q2 | 103.73 Million CNY | 48.12% |
| 2016 Q1 | 70.03 Million CNY | -28.68% |
| 2015 FY | 286.3 Million CNY | 20.78% |
| 2015 Q4 | 98.19 Million CNY | 60.16% |
| 2015 Q3 | 61.3 Million CNY | -21.04% |
| 2015 Q2 | 77.64 Million CNY | 57.96% |
| 2015 Q1 | 49.15 Million CNY | -21.31% |
| 2014 Q1 | 80.18 Million CNY | 0.0% |
| 2014 Q4 | 62.46 Million CNY | 2.34% |
| 2014 Q3 | 61.03 Million CNY | 84.46% |
| 2014 Q2 | 33.08 Million CNY | -58.74% |
| 2014 FY | 237.04 Million CNY | 65.61% |
| 2013 FY | 143.13 Million CNY | 23.88% |
| 2012 FY | 115.54 Million CNY | 27.24% |
| 2011 FY | 90.8 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 58.466% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.72 Billion CNY | 36.655% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | -157.661% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | -32.618% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | -106.684% |
| Maccura Biotechnology Co.Ltd | 1.51 Billion CNY | -14.089% |
| Guangdong Hybribio Biotech Co.,Ltd. | 662.35 Million CNY | -160.364% |
| BGI Genomics Co., Ltd. | 2.17 Billion CNY | 20.551% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | -97.871% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 329.31 Million CNY | -423.671% |